Sugi Predict

Sugi Predict / Compounds / SCHEMBL6235795

SCHEMBL6235795

SCHEMBL6235795

CCCCC(Oc1ccccc1C=O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 5/20 0.49
▸ PTGES O14684 1/20 0.49
▸ ALOX5 P09917 1/20 0.49
▸ PTGDR2 Q9Y5Y4 1/20 0.47
▸ PPARA Q07869 4/20 0.45
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CTRC Q99895 1/20 0.41
▸ RAD52 P43351 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CTSK P43235 5/20 0.39
▸ CTSL P07711 2/20 0.39
▸ CTSB P07858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25757370 0.95 CTRC (0.47) PPARGPTGESALOX5PTGDR2PPARA
SCHEMBL2557672 0.92 PPARG (0.54) PPARGPTGESALOX5PTGDR2PPARA
SCHEMBL11755152 0.86 TDP1 (0.42) PPARGPTGESALOX5PTGDR2KMT2A
SCHEMBL6459702 0.86 PTGDR2 (0.41) PTGDR2KMT2AMEN1KDM4ERECQL
SCHEMBL5442704 0.85 PTGDR2 (0.51) PPARGPTGDR2PPARAKMT2AMEN1
SCHEMBL14707709 0.83 PPARG (0.44) PPARGPTGESALOX5PTGDR2PPARA
SCHEMBL7642845 0.82 PTGDR2 (0.38) PPARGPTGESALOX5PTGDR2KMT2A
SCHEMBL2330339 0.82 PPARA (0.44) PPARGPTGESALOX5PTGDR2PPARA
SCHEMBL2547539 0.82 PTGDR2 (0.51) PPARGPTGESALOX5PTGDR2PPARA
SCHEMBL30639267 0.81 CTRC (0.54) PPARGPTGESALOX5PPARAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4448503-A1 PROCESS FOR THE PREPARATION OF BENZOFURANS Cambrex Profarmaco Milano S.r.l. (IT) 2024-10-23 — — EP claimed
CN-114539193-B Preparation method of amiodarone hydrochloride intermediate 安徽普利药业有限公司 2024-08-06 — — CN claimed
CN-118401503-A Process for the preparation of benzofurans 坎布雷普佛马可米兰有限公司 2024-07-26 — — CN claimed
WO-2023110528-A1 PROCESS FOR THE PREPARATION OF BENZOFURANS CAMBREX PROFARMACO MILANO S.R.L. (IT) 2023-06-22 — — WO claimed
CN-114539193-A Preparation method of amiodarone hydrochloride intermediate 海南普利制药股份有限公司 2022-05-27 — — CN claimed
EP-4448503-A1 PROCESS FOR THE PREPARATION OF BENZOFURANS Cambrex Profarmaco Milano S.r.l. (IT) 2024-10-23 — — EP disclosed
CN-114539193-B Preparation method of amiodarone hydrochloride intermediate 安徽普利药业有限公司 2024-08-06 — — CN disclosed
CN-118401503-A Process for the preparation of benzofurans 坎布雷普佛马可米兰有限公司 2024-07-26 — — CN disclosed
WO-2023110528-A1 PROCESS FOR THE PREPARATION OF BENZOFURANS CAMBREX PROFARMACO MILANO S.R.L. (IT) 2023-06-22 — — WO disclosed
WO-2023110528-A1 PROCESS FOR THE PREPARATION OF BENZOFURANS CAMBREX PROFARMACO MILANO S.R.L. (IT) 2023-06-22 — — WO disclosed
CN-114539193-A Preparation method of amiodarone hydrochloride intermediate 海南普利制药股份有限公司 2022-05-27 — — CN disclosed
CN-114539193-A Preparation method of amiodarone hydrochloride intermediate 海南普利制药股份有限公司 2022-05-27 — — CN disclosed
US-20050113596-A1 Nitrating a 2-(2-formylphenoxy) or 2-(2-formylphenylsulfido) alkyl ester or alkoic acid in the presence of sulfuric acid SHASUN PHARMA SOLUTIONS, INC. 2005-05-26 — — US disclosed
US-6855842-B1 Intermediates for making a bezofuran or benzothiophene derivative nitrated in position 5 and uses thereof RHODIA CHIMIE (FR) 2005-02-15 — — US disclosed
EP-1222181-B1 METHOD FOR PREPARING A BENZOFURAN OR BENZOTHIOPHENE COMPOUND RHODIA CHIMIE SA (FR) 2003-12-10 — — EP disclosed
US-6555697-B1 Cyclizing a 1-(2-carboxyethyloxy or thio-),2-formylbenzene in the presence of an efficient amount of a carbonate base in a medium comprising a carboxylic acid anhydride; intermediate for 2-n-butyl-5-nitrobenzofuran RHODIA CHIMIE (FR) 2003-04-29 — — US disclosed
EP-1222159-A2 INTERMEDIATES FOR MAKING A BENZOFURAN OR BENZOTHIOPHENE DERIVATIVE NITRATED IN POSITION 5 AND USES THEREOF RHODIA CHIMIE (FR) 2002-07-17 — — EP disclosed
EP-1222181-A1 METHOD FOR PREPARING A BENZOFURAN OR BENZOTHIOPHENE COMPOUND RHODIA CHIMIE (FR) 2002-07-17 — — EP disclosed
WO-2001029019-A1 METHOD FOR PREPARING A BENZOFURAN OR BENZOTHIOPHENE COMPOUND RHODIA CHIMIE (FR) 2001-04-26 — — WO disclosed
WO-2001028974-A2 INTERMEDIATES FOR MAKING A BENZOFURAN OR BENZOTHIOPHENE DERIVATIVE NITRATED IN POSITION 5 AND USES THEREOF RHODIA CHIMIE (FR) 2001-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113596-A1 Nitrating a 2-(2-formylphenoxy) or 2-(2-formylphenylsulfido) alkyl ester or alkoic acid in the presence of sulfuric acid SULT1A1, SULT1E1, FPR1 PPARG 1985/4885PTGES 1468/4885ALOX5 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.